interview Archives - Page 4 of 13

Combined Radiotherapy, Anti-Angiogenic Medication, and Immunotherapy for Downstaging Treatment in Hepatocellular Carcinoma Complicated by Portal Vein

By Mourabit Halima 2024.01.17

Hepatocellular carcinoma (HCC) is one of the most common malignancies in China, with most patients diagnosed in the intermediate to advanced stages. The formation of portal vein tumor thrombus (PVTT) is a critical indicator of HCC progression, and patients with HCC combined with PVTT have a very poor prognosis. Previous studies have shown that low-dose radiotherapy can extend the survival of HCC patients with PVTT. From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) was held in Seoul, South Korea. At the conference, a team led by Academician Jiahong Dong, Dr. Gong Li, and Dr. Keran Li from Beijing Tsinghua Chang Gung Hospital, Tsinghua University, China, presented a clinical study (Abstract Number: PE-97), investigating whether PVTT is more sensitive to radiotherapy than the primary tumor and exploring the efficacy of downstaging treatment in HCC patients with PVTT through the combination of radiotherapy, anti-angiogenic medication, and immunotherapy. Hepatology Digest had the privilege of inviting Dr. Gong Li to share the results of this research and its clinical application prospects.

Dr. Huichuan Sun: Focusing on the Asia-Pacific Region, Leading the Frontier – Exploring Breakthroughs in the Treatment of Hepatobiliary Tumor

By Peter W. PENG 2024.01.17

The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) recently concluded in Seoul, South Korea, bringing together top experts in liver and biliary system tumors from around the world to discuss clinical hot topics and challenges. Dr. Huichuan Sun from Zhongshan Hospital, Fudan University, China, shares and interprets the latest developments and frontiers, including the Asia-Pacific consensus and groundbreaking research with us.

Dr. Xinwei Wang: The Molecular Landscape and Clinical Significance of Liver Cancer

By Mourabit Halima 2024.01.17

Liver cancer is one of the most prevalent and deadliest cancers in China. Due to the low early diagnosis rate of liver cancer in clinical practice, treatment options such as radical liver resection and transplantation face significant limitations. In recent years, there has been a surge in liver cancer genomics research, providing new insights into early diagnosis, patient stratification, and treatment prognosis. From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Conference (APPLE 2023) was held in Seoul, South Korea. During the conference, Dr. Xinwei Wang from the U.S. National Cancer Institute gave a special lecture on "The Molecular Landscape and Clinical Significance of Liver Cancer." Hepatology Digest had the privilege of inviting Dr. Wang to share recent significant developments in this research field and delve into the potential applications and prospects of liver cancer genomics research for early diagnosis and prognosis prediction.

Interview with Dr. Girard Deciphers at ELCC 2023

By Mourabit Halima 2024.01.17

The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the Proffered Paper 2 session. In an interview with Oncology Frontier he further discussed the significant research data released at ELCC 2023, the status of dual immune checkpoint inhibitor regimens in the treatment of driver gene-negative non-small cell lung cancer (NSCLC), and the treatment of EGFR exon 20 insertion mutations (ex20ins) subtype.

Dr. P. Garrido Lopez Interprets Latest Data from CHRYSALIS

By Mourabit Halima 2024.01.17

On the first day of the 2023 European Lung Cancer Congress (ELCC), during the oral presentation session, Dr. P. Garrido Lopez from Ramón y Cajal University Hospital in Madrid, Spain, presented the long-term efficacy, safety, and predictive factors of amivantamab in the treatment of platinum-treated EGFR exon 20 insertion (EGFR ex20ins) mutant advanced non-small cell lung cancer (NSCLC) patients in the CHRYSALIS trial (Abstract No. 3O). In an interview with "Tumor Insight," P. Garrido Lopez further elucidated the results of the CHRYSALIS trial and its clinical significance.

Dr. Huiqiang Huang: Just around the corner! Extranodal NK/T-cell lymphoma is ushering in the era of immunotherapy.

By Peter W. PENG 2024.01.16

Extranodal NK/T-cell lymphoma (ENKTCL) of nasal type is a rare subtype, commonly found in the Asian population and associated with the Epstein-Barr Virus (EBV). At present, the prognosis for patients remains poor, especially for relapsed/refractory (R/R) cases. From June 8 to 11, 2023, the 28th European Hematology Association (EHA) annual meeting was held in Frankfurt, Germany. A selected oral report (Abstract No.: S226) from the conference showed that the use of PD-1 inhibitors alone or in combination significantly improved the treatment of R/R ENKTCL patients. This study further confirmed that immune checkpoint inhibitors have become an important treatment option for R/R ENKTCL patients. Oncology Frontier invited Dr. Huiqiang Huang from Sun Yat-sen University Cancer Center to share the research findings and insights at the conference.

Bispecific Antibodies Bring New Progress in Follicular Lymphoma Treatment, New CD79b ADC Drugs Show Significant Value in DLBCL Treatment!

By Mourabit Halima 2024.01.16

The annual European Hematology Association (EHA) conference was recently held in Frankfurt, Germany, in a hybrid online and offline format. As the largest international conference in the European hematology field, the EHA meeting covered a wide range of scientific topics, clinical and basic research, including benign and malignant hematology, discussing the latest developments in the field of hematology. At this EHA conference, a study (abstract S224) by the team of Professor Ryan Jacobs from the Atrium Health Levine Cancer Institute in the U.S. explored the value of TNB-486 (targeting CD19/CD3) in the treatment of relapsed/refractory follicular lymphoma and achieved impressive results. As a result, Oncology Frontier interviewed Professor Ryan Jacobs on-site for a detailed interpretation of the latest developments in the treatment of follicular lymphoma and diffuse large B-cell lymphoma.

Dr. Jun Ma: On the immunotherapeutic progress and future trends for acute lymphoblastic leukemia based on the studies at EHA 2023

By Mourabit Halima 2024.01.16

The 28th European Hematology Association (EHA) meeting was held in Frankfurt, Germany from June 8 to June 11, 2023, adopting a hybrid online and offline conference format. As the largest international conference in the European hematology field, the EHA meeting shares topics in various scientific, clinical, and fundamental researches, covering both benign and malignant hematology and discussing the latest advances in hematology. In the treatment of acute lymphoblastic leukemia (ALL), there was significant progress made at this EHA meeting, mainly focused on immunotherapy. To further grasp the content in this area, Oncology Frontier interviewed Professor Ma Jun from the Harbin Institute of Hematology & Oncology and discussed this topic in detail.

Dr. Huaqing Wang: Primary Mediastinal B-Cell Lymphoma (PMBCL) Benefits More Significantly from Axi-Cel Treatment

By Mourabit Halima 2024.01.15

From June 8th to 11th, 2023, the 28th European Hematology Association Congress (EHA) will take place in Frankfurt, Germany, in both online and offline formats, organized by the European Hematology Society. As the largest international conference in the field of European hematology, the EHA Congress will cover various scientific topics, clinical and basic research, benign and malignant hematology, and discuss the latest developments in the field of hematology. At this year's EHA Congress, a study from Italy (abstract S231) explored the differences in the efficacy and survival outcomes of CAR-T cell therapy for different subtypes of B-cell lymphoma patients, drawing significant attention. To gain a deeper understanding of this study, Oncology Frontier conducted an exclusive interview with Professor Wang Huaqing from Tianjin People's Hospital of Nankai University, who provided detailed insights into the research.

Dr. Qian Jiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

By Mourabit Halima 2024.01.15

From June 8th-11th, 2023, the 28th European Hematology Association (EHA) conference was held in Frankfurt, Germany. At the EHA meeting, Professor Jiang Qian's team from Peking University People's Hospital reported on the results of a study on reducing treatment doses for Chronic Myeloid Leukemia (CML) patients after achieving major molecular remission (abstract S158). During the conference, the "Tumor Watch" publication interviewed Dr. Qian Jiang, who elaborated on the current status of CML treatment, future prospects, and the initial intent and primary outcomes of the dosage reduction study.